HK1025915A1 - Method of treating dry eye disease with purinergicreceptor agonist. - Google Patents

Method of treating dry eye disease with purinergicreceptor agonist.

Info

Publication number
HK1025915A1
HK1025915A1 HK00105346A HK00105346A HK1025915A1 HK 1025915 A1 HK1025915 A1 HK 1025915A1 HK 00105346 A HK00105346 A HK 00105346A HK 00105346 A HK00105346 A HK 00105346A HK 1025915 A1 HK1025915 A1 HK 1025915A1
Authority
HK
Hong Kong
Prior art keywords
triphosphate
subject
disclosed
methods
liquid
Prior art date
Application number
HK00105346A
Other languages
English (en)
Inventor
Benjamin R Yerxa
Karla M Jacobus
William Pendergast
Janet L Rideout
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25170925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1025915(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of HK1025915A1 publication Critical patent/HK1025915A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
HK00105346A 1997-02-06 2000-08-25 Method of treating dry eye disease with purinergicreceptor agonist. HK1025915A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds
PCT/US1998/002701 WO1998034593A1 (fr) 1997-02-06 1998-02-06 Procede pour traiter la kerotoconjonctivite seche grace a des agonistes recepteurs purinergiques

Publications (1)

Publication Number Publication Date
HK1025915A1 true HK1025915A1 (en) 2000-12-01

Family

ID=25170925

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105346A HK1025915A1 (en) 1997-02-06 2000-08-25 Method of treating dry eye disease with purinergicreceptor agonist.

Country Status (20)

Country Link
US (6) US5900407A (fr)
EP (1) EP1003474B1 (fr)
JP (3) JP3652707B2 (fr)
KR (1) KR100378443B1 (fr)
CN (1) CN1151775C (fr)
AT (1) ATE428400T1 (fr)
AU (1) AU735684B2 (fr)
BR (1) BR9809562A (fr)
CA (1) CA2280183C (fr)
DE (1) DE69840746D1 (fr)
DK (1) DK1003474T3 (fr)
ES (1) ES2325892T3 (fr)
HK (1) HK1025915A1 (fr)
ID (1) ID23375A (fr)
MY (1) MY120023A (fr)
NO (1) NO329118B1 (fr)
NZ (1) NZ337405A (fr)
PT (1) PT1003474E (fr)
WO (1) WO1998034593A1 (fr)
ZA (1) ZA98979B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
JP3723227B2 (ja) * 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
EP1087777B1 (fr) * 1998-05-22 2003-02-19 Inspire Pharmaceuticals, Inc. Dinucleotides therapeutiques et leurs derives
WO2000039145A1 (fr) * 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Transfert genique cible utilisant des recepteurs couples a une proteine g
CA2359891A1 (fr) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Methode favorisant l'hydratation des muqueuses a l'aide de certains uridine, adenine et cytidine diphosphates et de leurs analogues
CZ303172B6 (cs) * 1999-06-30 2012-05-09 Inspire Pharmaceuticals, Inc. Krystalická forma P1-(2'-deoxycytidin-5'-)P4-(uridin-5'-)tetrafosfátu
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001028528A1 (fr) * 1999-10-20 2001-04-26 Eliezer Rapaport Procedes, compositions pharmaceutiques et therapeutiques destines a l'administration d'adenosine
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
CA2413928C (fr) * 2000-05-30 2011-01-25 Santen Pharmaceutical Co., Ltd. Promoteurs de l'extension de l'epithelium corneen
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
JP3945625B2 (ja) * 2001-03-30 2007-07-18 株式会社イーエムアイ 角膜上皮障害モデル動物及びそのモデル動物を用いた薬剤の評価方法並びにその評価方法を用いて選択された薬剤
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
AU2002342672A1 (en) * 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
WO2003028712A2 (fr) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US20030109488A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
BR0213179A (pt) * 2001-10-11 2004-09-14 Alcon Inc Métodos para tratamento de olhos secos por uma combinação de um esteróide antiinflamatório e um secretagogo de muc-1
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CA2502600A1 (fr) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methodes de traitement de la maladie de l'oeil sec avec des lantibiotiques
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005115432A2 (fr) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1848541A4 (fr) * 2005-02-07 2013-01-16 Pharmalight Inc Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
BRPI0621052A2 (pt) * 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
CA2749537C (fr) * 2009-01-09 2018-11-20 The Schepens Eye Research Institute, Inc. Compositions antagoniste il-1 destinee a la regeneration et la protection du nerf corneen
WO2011106697A1 (fr) 2010-02-25 2011-09-01 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement de la maladie de l'œil sec
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
EP2555751B8 (fr) 2010-04-03 2018-02-14 Praful Doshi Procédés pour le revetement d'une lentille de contact
CN106729718A (zh) * 2010-09-10 2017-05-31 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
AU2011328900B2 (en) 2010-11-16 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
EP2659894A4 (fr) * 2010-12-28 2014-12-10 Santen Pharmaceutical Co Ltd Solution ophtalmique contenant du diquafosol, son procédé de production, et procédé de prévention de la formation d'un précipité insoluble
EP2694983B1 (fr) * 2011-04-06 2020-06-03 KLA-Tencor Corporation Procédé et système pour produire une métrique de qualité pour commande de processus améliorée
UA113981C2 (xx) 2012-03-26 2017-04-10 Офтальмологічний розчин, що містить диквафасол
EP2967817B1 (fr) 2013-03-12 2021-03-10 Oculeve, Inc. Dispositifs et systèmes de pose d'implant
CA2883874A1 (fr) 2013-04-19 2014-10-23 Oculeve, Inc. Dispositifs et procedes de stimulation nasale
ES2812752T3 (es) 2014-02-25 2021-03-18 Oculeve Inc Formulaciones de polímeros para estimulación nasolagrimal
EP3171928B1 (fr) 2014-07-25 2020-02-26 Oculeve, Inc. Stimulation pulsée pour traiter l'oeil sec
EP3209371A4 (fr) 2014-10-22 2018-10-24 Oculeve, Inc. Systèmes et procédés de stimulateur nasal implantable
EP3209370A4 (fr) 2014-10-22 2018-05-30 Oculeve, Inc. Lentille de contact permettant une augmentation de la production de larmes
CN107106843A (zh) 2014-10-22 2017-08-29 奥库利维公司 用于治疗干眼症的刺激装置和方法
KR20180014768A (ko) 2015-06-05 2018-02-09 산텐 세이야꾸 가부시키가이샤 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
CA3022683A1 (fr) 2016-05-02 2017-11-09 Oculeve, Inc. Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blepharite
JP2020500609A (ja) 2016-12-02 2020-01-16 オキュリーブ， インコーポレイテッド ドライアイ予測及び治療勧告のための装置及び方法
MX2020008925A (es) 2018-02-28 2020-10-01 Santen Pharmaceutical Co Ltd Composicion oftalmica que comprende dicuafosol y polimero cationico.
JPWO2020175525A1 (ja) 2019-02-27 2021-12-23 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2021039748A1 (fr) * 2019-08-27 2021-03-04 参天製薬株式会社 Diquafosol ou sel correspondant et composition ophtalmique aqueuse contenant de la polyvinylpyrrolidone
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330902A1 (de) * 1973-06-18 1975-03-20 Helmut Dr Med Zander Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel
US4380239A (en) 1979-12-20 1983-04-19 The Hospital For Sick Children Intubation of lacrimal ducts
US4658816A (en) 1984-11-14 1987-04-21 Concept Incorporated Lighted canaliculus intubation sets
US4868154A (en) * 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5062831A (en) 1988-09-28 1991-11-05 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US4921485A (en) 1988-09-28 1990-05-01 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5169386A (en) 1989-09-11 1992-12-08 Bruce B. Becker Method and catheter for dilatation of the lacrimal system
US5021043A (en) 1989-09-11 1991-06-04 C. R. Bard, Inc. Method and catheter for dilatation of the lacrimal system
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5345948A (en) 1993-04-08 1994-09-13 Donnell Jr Francis E O Method of performing translactrimal laser dacryocystorhinostomy
CN1229114C (zh) * 1996-03-27 2005-11-30 印斯拜尔药品股份有限公司 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
TW567456B (en) * 2001-02-15 2003-12-21 Au Optronics Corp Apparatus capable of improving flicker of thin film transistor liquid crystal display
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples

Also Published As

Publication number Publication date
CN1151775C (zh) 2004-06-02
US6887858B1 (en) 2005-05-03
KR20000070848A (ko) 2000-11-25
US7759322B2 (en) 2010-07-20
PT1003474E (pt) 2009-06-26
US20100330164A1 (en) 2010-12-30
NO993777D0 (no) 1999-08-04
JP3652707B2 (ja) 2005-05-25
EP1003474B1 (fr) 2009-04-15
NZ337405A (en) 2001-07-27
US20080009463A1 (en) 2008-01-10
JP5373576B2 (ja) 2013-12-18
CA2280183C (fr) 2008-04-22
ATE428400T1 (de) 2009-05-15
ZA98979B (en) 1999-02-19
US6916794B2 (en) 2005-07-12
NO993777L (no) 1999-10-05
JP2010111676A (ja) 2010-05-20
NO329118B1 (no) 2010-08-30
JP2001504858A (ja) 2001-04-10
US7235535B2 (en) 2007-06-26
US20020103157A1 (en) 2002-08-01
AU735684B2 (en) 2001-07-12
KR100378443B1 (ko) 2003-03-29
CN1250369A (zh) 2000-04-12
US8097600B2 (en) 2012-01-17
US5900407A (en) 1999-05-04
BR9809562A (pt) 2001-10-02
WO1998034593A1 (fr) 1998-08-13
JP2005015491A (ja) 2005-01-20
ES2325892T3 (es) 2009-09-23
EP1003474A1 (fr) 2000-05-31
JP4664027B2 (ja) 2011-04-06
DK1003474T3 (da) 2009-07-20
MY120023A (en) 2005-08-30
AU6324198A (en) 1998-08-26
DE69840746D1 (de) 2009-05-28
ID23375A (id) 2000-04-20
US20050197316A1 (en) 2005-09-08
CA2280183A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
HK1025915A1 (en) Method of treating dry eye disease with purinergicreceptor agonist.
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
CA2250188A1 (fr) Methode de traitement de la dyskinesie ciliaire avec des uridine triphosphates et des composes apparentes
WO2001080844A3 (fr) Methode de traitement de la keratoconjonctivite seche a l'aide d'agonistes des recepteurs de l'acetylcholine
US5972904A (en) Method of treating sinusitis with uridine triphosphates and related compounds
NZ313864A (en) Method of obtaining a mucous sample from the lung using triphosphate compounds
HK1028613A1 (en) Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof.
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
WO1998003182A3 (fr) Utilisation d'uridine triphosphates et de composes apparentes pour prevenir et traiter la pneumonie chez des patients immobilises
WO2007022541A3 (fr) Procede permettant de traiter la keratoconjonctivite seche par des histamines non dessechantes
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
US6696425B2 (en) Method of treating dry eye disease with purinergic receptor agonists
IT1254280B (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
EP0397211A3 (fr) Administration percutanée de la 3'-azido-3'-déoxythymidine
US4044122A (en) Method of treating herpes virus hominis infections
WO1999065501A1 (fr) Procede pour traiter un empoisonnement aux composes organophosphores

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180205